Concord Biotech Ltd
Company Profile
Business description
Concord Biotech Ltd is a bio-pharmaceutical company specializing in manufacturing Active Pharmaceutical Ingredients (APIs) and high-quality Finished formulations. It is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. The Company's API manufacturing facilities are located at Dholka and Limbasi, and its formulations facility at Valthera in the state of Gujarat, India. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The company has single operating segment. The company has presence in India, United States of America, and Others. The company generates majority of revenue from India. Its products are Active Pharmaceutical Ingredients, and Formulation.
Contact
Iscon Cross Road, S.G. Highway
B-1601-1602, B-Wing, Mondeal Heights, 16th Floor
AhmedabadGJ380015
INDT: +91 7968138700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
2,899
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,445.10 | 33.80 | 0.36% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,668.03 | 137.75 | 0.54% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 65,606.71 | 76.55 | -0.12% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,263.60 | 34.80 | 0.38% |
| SSE Composite Index | 3,940.04 | 39.68 | 1.02% |